8
NEWS
Dedicated NHS Diabetes Advice helpline
0345 123 2399
Omnipod 5 HCL
Insulet has announced positive results from a clinical trial showing improved
glycaemic and patient-reported outcomes in Type 1 diabetes with the Omnipod
5 automated insulin delivery (AID) system. Compared to non-automated insulin
therapy.
Insulet's Omnipod 5 was the first tubeless, wearable automated insulin
delivery system cleared for marketing in the US.
The trial surveyed 194 adults in the US and France who had Type 1 diabetes
for at least one year, with HbA1c between 7% and 11%, and who had used
traditional (non-AID) therapy. That included 87% using previous-generation
Omnipod or Omnipod Dash systems.
Participants were split into two randomized groups: the control group (62
subjects) used their usual pump with Dexcom G6 CGM, while the intervention
group (132 subjects) used Omnipod 5 with the G6.
Insulet reported that Omnipod 5 users showed a greater reduction in HbA1c
(0.58%) difference, as well as a 17.5% improvement in time in range totalling an
additional 4.2 hours per day. They saw a significantly lower mean glucose and
time above 10mmols/L and also spent significantly less time below 3.9mmols/L.
FDA Wegovy and
the heart
The FDA has approved Wegovy to reduce
cardiovascular risk in people with obesity, based on
results from Novo Nordisk's SELECT trial.
Excess weight raises the risk of Type 2 diabetes,
heart attacks, and stroke, but the SELECT clinical trial
has shown that showed Wegovy (semaglutide) can
significantly reduce weight and lower the chance of
cardiovascular events by 20%.
The survey included over 17,600 adults aged 45
years and older with overweight or obesity and a prior
history of heart disease but who did not have diabetes.
It found that, over five years, participants taking 2.4
mg of semaglutide saw a 20% reduction in heart
attacks, stroke, and heart-related deaths, regardless
of adherence, or how consistently participants took
Wegovy.
The FDA ruling highlights the use of Wegovy to
reduce risks of major adverse cardiovascular events,
including cardiovascular death, non-fatal heart attack,
or non-fatal stroke in adults with either overweight or
obesity and established cardiovascular disease. Wegovy
maker Novo Nordisk has also filed for a label expansion
in the EU, with a decision also expected in 2024.
T1D 'at risk' registry
Oxford University researchers are to set up the first
UK registry for children and adults at risk of Type 1
diabetes. The team will build a database and website
that will list those who test positive for diabetes
autoantibodies, which appear when the insulinproducing
beta cells in the pancreas are damaged, and
are the most reliable indicator that a person is likely to
develop the condition.
It is believed that half the people who have positive
autoantibodies are no longer followed up as they
are not involved in research studies. This leads to a
limited understanding of those people living with them,
researchers say.
Researchers hope it will help them better
understand the care and support people at high risk
of Type 1 require, as well as what it is like being at
high risk, and enable them to develop resources to
support people and so avoid anxiety and worry. The
data collected could also indicate whether being at risk
causes people to attend their GP or A&E more often.
The registry will be held at the Diabetes Trials Unit
at the University of Oxford and recruitment is expected
to start later this year.
To find out more, CLICK HERE.